Focus List

GENETEX WEBINAR: RAS genes in development and cancer

GENETEX WEBINAR SERIES 2022

GENETEX WEBINAR SERIES 2022

RAS genes in development and cancer

by Matthias Drosten, Ph.D.,
Group Leader, Centro de Investigación del Cáncer (CIC-IBMCC), Salamanca, Spain

RAS genes have gained prominence due to their implication in human cancer. Mammals harbor three RAS loci (HRAS, NRAS, and KRAS) that are found mutated in many different tumor types, albeit with clear tissue-selective preferences for individual RAS loci. Moreover, whereas HRAS and NRAS produce only one major protein, the KRAS locus gives rise to two different protein isoforms via alternative splicing of the final exon. Thus, all four RAS proteins differ in the C-terminal hypervariable region that determines how RAS proteins are anchored to the cell membrane. Despite these differences, RAS proteins share common biochemical features and participate in similar activities. In his webinar, Dr. Drosten will focus on three fundamental aspects of RAS biology: (1) What is the biological difference between the three RAS genes and what is their role in normal homeostasis? (2) What is the (differential) role of RAS paralogs in cancer? (3) What are the contributions of each of the KRAS isoforms to development and cancer? He will explain how mouse models have been crucial in revising some of the classical concepts of RAS biology.

 
When: Wednesday, October 5, 2022, at 4:00 pm (CEST)

ARIGO GAINDATA

ARIGO is proud to launch an in-house developed GainDataTM (ELISA analysis tool, web based free service).

Researchers just simply copy their ELISA data from excel and paste to our GainDataTM  then  follow the tool, less than a minute the result will be calculated automatically.

You could find more GainDataTM information on ARIGO landing page 

MIRUS REAGENT AGENT

The Transfection Experts bring you the Reagent Agent® - a tool designed to help you determine the best delivery solution for any nucleic acid into any cell type including hard-to-transfect cell lines and primary cells.

Reagent Agent® recommendations are based on extensive in-house transfection and electroporation data, customer feedback, and citations that are all continually updated.